Jeff is traveling, so we are republishing his recent interview from the Kirk Report, one of our featured sources.  The Kirk Report is an excellent investor resource, with many specific stock ideas for members.  Charles Kirk also reads very widely and provides regular links to articles we might otherwise have missed.  He came up with some excellent questions for the interview, getting Jeff to discuss many topics he has not covered on "A Dash." Here is the Kirk Report interview: It is with great pleasure to have Jeff Miller, from A Dash Of Insight, to participate in this month's Q&A. Many of you know Jeff because I've linked to many (if not the vast majority) of his blog posts. In this Q&A we'll cover a variety of topics ...

Tuesday 10/14/08

Navivest

Genentech, Inc. (DNA) today after the close of the stock market, announced earnings results for the third quarter of 2008. According to the company, key results for the third quarter of 2008 include:

U.S. product sales of $2,452 million, a 14 percent increase from U.S. product sales of $2,155 million in the third quarter of 2007.

Non-GAAP operating revenue of $3,408 million1, a 17 percent increase from operating revenue of $2,905 million in the third quarter of 2007; GAAP operating revenue of $3,412 million, a 17 percent increase from operating revenue of $2,908 million in the third quarter of 2007.

Non-GAAP net income of $863 million, an 11 percent increase from $778 million in the third quarter of 20071; GAAP net income of $731 million, a 7 percent increase from $685 million in the third quarter of 2007.

Non-GAAP earnings per share of $0.81, an 11 percent increase from $0.73 in the third

...

According to the Alzheimer’s Association, approximately 5.2 million Americans are living with Alzheimer’s. Someone develops Alzheimer’s every 71 seconds, and it is the sixth-leading cause of death. To fight the mental, physical and emotional devastation this disease causes individuals, family and friends, Memory Pharmaceuticals Corp. (Nasdaq: MEMY) is focused on developing innovative drugs for the treatment of debilitating CNS disorders that may impair memory and other cognitive functions, including Alzheimer’s disease and schizophrenia.

The company today announced the completion of its phase I multiple ascending dose study of R4996/MEM 63908. The study is the fourth and final study involving health volunteers to determine the efficacy of the nicotinic alpha-7 receptor being developed in collaboration with Roche.

Per the agreement, Memory Pharmaceuticals is responsible for conducting the clinical trials, while Roche is responsible for later-stage development and commercialization.

“We conducted a robust and comprehensive phase 1 program for R4996/MEM 63908, during which

...